PrognomiQ Announces $34 Million Series D Financing to Advance Development of Early Detection Test for Lung Cancer with Multi-omics Platform

– New Appointment of Isaac Ro to Board of Directors Brings Broad Diagnostic Industry & Operations Experience to Company –

SAN MATEO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- PrognomiQ, a healthcare company focused on harnessing the power of multi-omics data to transform the detection and early treatment selection and monitoring of cancer and other complex diseases, today announced the company's Series D financing of $34 million led by Seer, Inc., with participation from a new, large, strategic investor in the Diagnostics segment as well as from existing investors, including Catalio Capital Management, aMoon, Invus and Bruker. The closing of this round brings PrognomiQ's total funding to more than $135 million since the company was founded in September 2020.

PrognomiQ will use this round of funding to advance development of an early detection test for lung cancer, which the company plans to provide as a lab developed test (LDT) and later as an In Vitro Diagnostics (IVD) test. PrognomiQ was recently granted a Clinical Laboratory Improvement Amendment (CLIA) license to support the development of the LDT product, and it is currently enrolling a prospective 15,000 subject study in lung cancer, initiated in 2023 to support registration of the IVD product.

Additionally, concurrent with this financing, Isaac Ro has joined PrognomiQ's Board as an Independent Director. Isaac brings broad experience as an investor, operating executive and equity research analyst in the Diagnostics industry. He is currently a Partner with Catalio Capital Management. He recently served as Executive Chair of Haystack Oncology, and prior to that, as Chief Financial Officer of ...